样本编号	SAMC4883072
外部数据库编号	GSA-Human: HRS1635117
样品名称	ECPRES061_ctDNA_pp_CRE2
样本标题	ECPRES061_ctDNA_pp_CRE2.bam
样品类型	Human sample
物种名称	Homo sapiens
描述信息	Targeted sequencing of plasma samples collected at second clinical response evaluation (CRE2) using a personalized panel of up to 50 highly ranked variants
样本属性	*该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA010802数据获取。
发布日期	2025-06-24
项目编号	PRJCA036459
提交者	Zhigang Li (zhigang.li@shsmu.edu.cn)
提交单位	Shanghai Chest Hospital, Shanghai Jiao Tong University School of medicine
提交日期	2025-03-22

样本包含数据信息

资源名称	描述
GSA-Human (1)	-
HRA010802 (Controlled Access)	Patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (nCRT) were enrolled in this molecular residual disease (MRD) study. Baseline tumor tissue samples and serial blood samples were collected (baseline, post-nCRT [CRE-1 and CRE-2], and post-surgery [1 month, F1; and 3-to-6 months, F2]). This study assessed the feasibility of circulating tumor DNA (ctDNA) in detecting residual disease after nCRT to improve the selection of patients for a watch-and-wait strategy and stratification of postsurgical recurrence risk to guide adjuvant treatment.

资源名称

描述

GSA-Human (1)

HRA010802 (Controlled Access)

Patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (nCRT) were enrolled in this molecular residual disease (MRD) study. Baseline tumor tissue samples and serial blood samples were collected (baseline, post-nCRT [CRE-1 and CRE-2], and post-surgery [1 month, F1; and 3-to-6 months, F2]). This study assessed the feasibility of circulating tumor DNA (ctDNA) in detecting residual disease after nCRT to improve the selection of patients for a watch-and-wait strategy and stratification of postsurgical recurrence risk to guide adjuvant treatment.